Corpus overview


MeSH Disease

Human Phenotype



There are no seroprevalence terms in the subcorpus

    displaying 1 - 3 records in total 3
    records per page

    Cancer inpatient with COVID-19: a report from the Brazilian National Cancer Institute

    Authors: Andreia C de Melo; Luiz Claudio S Thuler; Jesse L da Silva; Lucas Z de Albuquerque; Ana Carla Pecego; Luciana O.R. Rodrigues; Magda S da Conceicao; Marianne M Garrido; Gelcio L Mendes; Ana Cristina M Pereira; Marcelo A Soares; Joao P.B. Viola; - INCA COVID-19 Task Force

    doi:10.1101/2020.06.27.20141499 Date: 2020-06-29 Source: medRxiv

    Brazil has been recording a frightening exponential curve of confirmed cases TRANS of SARS-CoV-2 infection MESHD. Cancer patients with COVID-19 are likely to have a greater risk of complications and death MESHD. A retrospective search in the electronic medical records of cancer inpatients admitted to the Brazilian National Cancer Institute from April 30, 2020 to May 26, 2020 granted identification of 181 patients with COVID-19 confirmed by RT-PCR method. The mean age TRANS was 55.3 years (SD 21.1). The most prevalent solid tumors were breast (40 [22.1%]), gastrointestinal (24 [13.3%]), and gynecological (22 [12.2%]). Among hematological malignancies, lymphoma MESHD lymphoma HP (20 [11%]) and leukemia MESHD leukemia HP (10 [5.5%]) predominated. The most common complications were respiratory failure HP (70 [38.7%]), septic shock MESHD shock HP (40 [22.1%]) and acute kidney injury MESHD acute kidney injury HP (33 [18.2%]). A total of 60 (33.1%) patients died due to COVID-19 complications. By multivariate analysis, cases with admission due to symptoms of COVID-19 (p = 0.027) and with two or more metastatic sites (p <0.001) showed a higher risk of COVID-19-specific death MESHD. This is the first study in a cohort of Brazilian cancer patients with COVID-19. The rates of complications and COVID-19-specific death MESHD were significantly high. Our data prompts urgent and effective public policies for this group of especially vulnerable patients.

    Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: A structured summary of a study protocol for a randomised controlled trial.

    Authors: Abolghasem Allahyari; Hossein Rahimi; Majid Khadem-Rezaiyan; Zahra Mozaheb; Mohsen Seddigh-Shamsi; Alireza Bary; Mostafa Kamandi; Sajad Ataei Azimi; Saeed Eslami HasanbAbadi; Alireza Noferesti; Somayeh Sadat Shariatmaghani; Houshang Rafatpanah; Shohreh Khatami; Afshin Jabbar Imani; Hassan Mortazi; Mohammad Moeini Nodeh

    doi:10.21203/rs.3.pex-969/v1 Date: 2020-06-05 Source: ResearchSquare

    This is a multi-center, two-arm, parallel-group, triple-blind, phase 2-3 randomised controlled trial. All patients over the age TRANS of 15 from 5 types of cancer, acute lymphoid and myeloid leukemias MESHD myeloid leukemias HP, non-Hodgkin's lymphoma MESHD lymphoma HP, breast and colon cancer HP will enter the study. Patients are randomly assigned to two groups. During two months of treatment, the two groups are treated with either hydroxychloroquine or placebo. Patients will be monitored for COVID-19 symptoms. The primary end point of the study is to investigate the incidence of COVID-19 in patients.Randomisation will be performed using randomly permuted blocks. The allocation ratio in two groups is 1:1. Participants, caregivers, outcome assessor and the data analyst are blinded to group assignment.The calculated total sample size is 60 patients, with 30 patients in each group. The trial began on April 14, 2020 and recruitment is ongoing. Recruitment is anticipated to be completed by June 14, 2020. This trial has been registered on the Iranian Registry of Clinical Trials (IRCT) with the registration number of IRCT20200405046958N1.

    Evaluation of COVID 19 infection MESHD in 279 cancer patients treated during a 90-day period in 2020 pandemic

    Authors: Mozaffar Aznab

    doi:10.1101/2020.05.26.20102889 Date: 2020-06-01 Source: medRxiv

    Background: The aim of this study was investigation of COVID-19 disease MESHD and its outcome in cancer patients who needed treatment, in a 90-day period. Methods: Cancer patient who required treatment, were evaluated for potential COVID-19 infection MESHD in a 90-day period, starting from beginning of this epidemic in Iran, January, to April 19, 2020. For treatment of solid tumor patients, if they did not have symptoms related to COVID-19, just chest X-ray was requested. If they showed COVID-19 related symptoms, High Resolution CT scan of lungs was requested. For hematology cancer patients, PCR test for COVID-19 infection MESHD was requested as well. Protection measures were considered for personnel of oncology wards. Results: In this study, 279 patients were followed up in this 90-day period. No COVID-19 infection MESHD was observed in 92 cases of breast cancer, 72 cases of colon cancer HP, 14 cases of gastric cancer and 12 cases of pancreaticobiliary cancer .However, in 11 cases of lung cancer, 5 cases brain tumors and 12 cases ovarian cancer; 3 case of COVID-19 were observed. In the hematology cancers group, which included 14 cases of Hodgkin Lymphoma HP Lymphoma MESHD, 23 cases of lymphoproliferative disorder MESHD lymphoproliferative disorder HP, 12 cases of acute leukemia HP leukemia MESHD and 12 cases of multiple myeloma MESHD multiple myeloma HP; three of COVID-19 were observed. Conclusion: Patients with cancer who need treatment can be treated by taking some measures. These measures include observing individual and collective protection principles in patients and health-care personnel, increasing patients awareness particularly about self-care behavior, performing a COVID-19 test, and taking a chest X ray, before the treatment starts

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.